Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Strongbridge Biopharma expects cash to fund operations through 1Q22  07:37
08/04/20
08/04
07:37
08/04/20
07:37
SBBP

Strongbridge Biopharma

$3.57 /

+0.21 (+6.25%)

 
ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

Hot Stocks
Strongbridge Biopharma expects results from LOGICS study in September » 07:37
08/04/20
08/04
07:37
08/04/20
07:37
SBBP

Strongbridge Biopharma

$3.57 /

+0.21 (+6.25%)

The Company anticipates…

The Company anticipates that it will report top-line results from the LOGICS study in September 2020. The Company continues to anticipate submitting a New Drug Application for RECORLEV to the FDA approximately six months after reporting top-line LOGICS results.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

Earnings
Strongbridge Biopharma sees FY20 KEVEYIS revenue $22M-$26M » 07:36
08/04/20
08/04
07:36
08/04/20
07:36
SBBP

Strongbridge Biopharma

$3.57 /

+0.21 (+6.25%)

Revenue consensus…

Revenue consensus $25.22M.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

Earnings
Strongbridge Biopharma reports Q2 adj. EPS (12c), consensus (21c) » 07:36
08/04/20
08/04
07:36
08/04/20
07:36
SBBP

Strongbridge Biopharma

$3.57 /

+0.21 (+6.25%)

Reports Q2 revenue…

Reports Q2 revenue $7.76M, consensus $6M. "Strongbridge had an impressive second quarter as we executed upon a number of critical milestones across our rare disease portfolio. We recently announced the achievement of the last participant completing the last study visit in the randomized withdrawal phase of the Phase 3 LOGICS study of RECORLEV, and we look forward to reporting top-line data in September 2020," said John H. Johnson, chief executive officer of Strongbridge Biopharma. "Additionally, KEVEYIS revenue grew by 38 percent in the first-half of 2020 compared to the same period in 2019. Importantly, this growth was achieved despite the challenges posed by the COVID-19 pandemic, which has impacted the biopharmaceutical industry as a whole. Given our strong first half performance, we expect to achieve, or potentially exceed, the higher end of our full-year 2020 KEVEYIS revenue guidance range of $22 million to $26 million."

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.57 /

+0.21 (+6.25%)

Over a week ago
Conference/Events
Strongbridge Biopharma management to meet virtually with Oppenheimer » 04:55
07/14/20
07/14
04:55
07/14/20
04:55
SBBP

Strongbridge Biopharma

$3.30 /

-0.23 (-6.52%)

Virtual Meeting to be…

Virtual Meeting to be held on July 14 hosted by Oppenheimer.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.30 /

-0.23 (-6.52%)

SBBP Strongbridge Biopharma
$3.30 /

-0.23 (-6.52%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.30 /

-0.23 (-6.52%)

Conference/Events
Strongbridge Biopharma management to meet virtually with Oppenheimer » 09:15
07/13/20
07/13
09:15
07/13/20
09:15
SBBP

Strongbridge Biopharma

$3.53 /

-0.13 (-3.55%)

Virtual Meeting to be…

Virtual Meeting to be held on July 14 hosted by Oppenheimer.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.53 /

-0.13 (-3.55%)

SBBP Strongbridge Biopharma
$3.53 /

-0.13 (-3.55%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.53 /

-0.13 (-3.55%)

Hot Stocks
Strongbridge Biopharma appoints John Johnson as CEO » 07:33
07/07/20
07/07
07:33
07/07/20
07:33
SBBP

Strongbridge Biopharma

$3.80 /

+0.13 (+3.54%)

Strongbridge Biopharma…

Strongbridge Biopharma announced that at the request of the board, John Johnson has agreed to become the CEO of Strongbridge. Johnson, who has served as chairman of Strongbridge since March 2015, assumed the position of executive chairman in November 2019 to lead the organization while the board conducted a formal search to identify a new CEO. Effective immediately, Johnson will assume the role of CEO of Strongbridge and remain a member of the company's board.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.80 /

+0.13 (+3.54%)

SBBP Strongbridge Biopharma
$3.80 /

+0.13 (+3.54%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.80 /

+0.13 (+3.54%)

Over a month ago
Hot Stocks
Strongbridge completes last study visit in withdrawal phase of LOGICS study » 07:55
07/01/20
07/01
07:55
07/01/20
07:55
SBBP

Strongbridge Biopharma

$3.79 /

-0.17 (-4.29%)

Strongbridge Biopharma…

Strongbridge Biopharma announced that the last participant has completed the last study visit in the randomized withdrawal phase of the LOGICS study for RECORLEV, its product candidate for the treatment of endogenous Cushing's syndrome. A total of 43 patients completed the randomized withdrawal phase of the study. The Phase 3 program for RECORLEV consists of SONICS and LOGICS: two multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat endogenous Cushing's syndrome. The SONICS study met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The LOGICS study is a double-blind, placebo-controlled randomized-withdrawal study of RECORLEV that is designed to supplement the long-term efficacy and safety information supplied by SONICS. The Company plans to submit a New Drug Application for RECORLEV to the FDA approximately six months after reporting topline LOGICS results.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.79 /

-0.17 (-4.29%)

SBBP Strongbridge Biopharma
$3.79 /

-0.17 (-4.29%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.79 /

-0.17 (-4.29%)

Hot Stocks
Strongbridge Biopharma announces $30M debt facility with Avenue » 07:36
05/20/20
05/20
07:36
05/20/20
07:36
SBBP

Strongbridge Biopharma

$3.45 /

+0.315 (+10.06%)

Strongbridge Biopharma…

Strongbridge Biopharma announced that it and its subsidiaries have entered into a $30M debt facility with Avenue Venture Opportunities Fund, L.P. Under the terms of the loan agreement, Strongbridge U.S. Inc., a subsidiary of Strongbridge Biopharma plc, borrowed $10M at closing. The debt facility also provides Strongbridge U.S. Inc., with two potential additional tranches of up to $10M each. The first additional tranche is available between October 1, 2020 and December 31, 2020 if the Company achieves positive top-line data for RECORLEV in its Phase 3 LOGICS clinical trial. The second additional tranche is available between October 1, 2021 and March 31, 2022 if the Company achieves FDA approval of RECORLEV, subject to approval from Avenue's investment committee. The debt facility has a four-year term, no minimum revenue or cash balance financial covenants and an interest-only period of up to 36 months assuming the Company achieves positive top-line data for RECORLEV in its Phase 3 LOGICS clinical trial and the Company receives FDA approval of RECORLEV. The Company believes that the new debt facility will extend its cash runway through the first quarter of 2022, which is at least two additional quarters beyond previous guidance. Pursuant to the loan agreement, Strongbridge issued to Avenue warrants to purchase up to 267,390 ordinary shares of Strongbridge at a per share exercise price of the lower of $1.87, or the effective price of any bona fide equity financing prior to December 31, 2020. Avenue also has the right to convert up to $3M of the principal outstanding of the loan into Strongbridge ordinary shares at a price per share of the lower of $2.24, or 20% above the effective price of any bona fide equity financing prior to December 31, 2020, subject to the terms and conditions described in the loan agreement.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.45 /

+0.315 (+10.06%)

SBBP Strongbridge Biopharma
$3.45 /

+0.315 (+10.06%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.45 /

+0.315 (+10.06%)

Conference/Events
Strongbridge Biopharma management to meet virtually with JMP Securities » 04:55
05/12/20
05/12
04:55
05/12/20
04:55
SBBP

Strongbridge Biopharma

$3.18 /

+0.33 (+11.58%)

Virtual Meeting with…

Virtual Meeting with management to be held on May 12 hosted by JMP Securities.

ShowHide Related Items >><<
SBBP Strongbridge Biopharma
$3.18 /

+0.33 (+11.58%)

SBBP Strongbridge Biopharma
$3.18 /

+0.33 (+11.58%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
03/03/20 Craig-Hallum
Strongbridge Biopharma initiated with a Buy at Craig-Hallum
09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
SBBP Strongbridge Biopharma
$3.18 /

+0.33 (+11.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.